Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)

European Journal of Cancer

Volumn 50, Issue 18, 2014, Pages 3116-3124

  Trouilloud, Isabelle ^a   Dupont Gossard, Anne Claire ^b   Malka, David ^c   Artru, Pascal ^d   Gauthier, Mélanie ^e   Lecomte, Thierry ^f   Aparicio, Thomas ^g   Thirot Bidault, Anne ^h   Lobry, Céline ⁱ   Asnacios, Amani ^j   Manet Lacombe, Sophie ^k   Fein, Francine ^b   Dubreuil, Olivier ^a   Landi, Bruno ^a   Zaanan, Aziz ^a   Bonnetain, Franck ^b   Taïeb, Julien ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Hopital Prive Jean Mermoz   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f UNIVERSITY HOSPITAL OF TOURS   (France)

^g UNIVERSITÉ PARIS 13   (France)

^h BICÊTRE HOSPITAL   (France)

ⁱ BICHAT HOSPITAL   (France)

^j HÔPITAL ANTOINE BÉCLÈRE   (France)

^k CENTRE HOSPITALIER RENÉ DUBOS   (France)

more..

Author keywords

FOLFIRI.3; Pancreatic cancer; Sequential chemotherapy

Indexed keywords

BILIRUBIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DEOXYCYTIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PROSPECTIVE STUDY; SECONDARY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84925226912     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.09.015     Document Type: Conference Paper

References (29)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. I. Trouilloud, O. Dubreuil, and T. Boussaha Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine Clin Res Hepatol Gastroenterol 35 2011 364 374
3. H.A. Burris, M.J. Moore, and J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
4. T. Conroy, F. Desseigne, and M. Ychou FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
5. D. Von Hoff, T. Ervin, and F. Arena Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 2013 1691 1703
6. H. Matsuoka, K. Yano, and Y. Seo Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates Anticancer Drugs 6 1995 413 418
7. D.J. Wagener, H.E. Verdonk, and L.Y. Dirix Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study Ann Oncol 6 1995 129 132
8. R. Klapdor, and C. Fenner Irinotecan(Campto R): efficacy as third/forth line therapy in advanced pancreatic cancer Anticancer Res 20 2000 5209 5212
9. A. Zaniboni, E. Aitini, and S. Barni FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study Cancer Chemother Pharmacol 69 2012 1641 1645
10. C.M. Rocha Lima, M.R. Green, and R. Rotche Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 2004 3776 3783
11. M. Hebbar, M. Ychou, and M. Ducreux Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer J Cancer Res Clin Oncol 135 2009 749 752
12. M. Ducreux, J.-L. Raoul, and P. Marti High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases? Oncology 74 2008 17 24
13. M. Mabro, P. Artru, and T. André A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients Br J Cancer 94 2006 1287 1292
14. S. Guichard, D. Cussac, and I. Hennebelle Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo Int J Cancer 73 1997 729 734
15. D.R. Mans, I. Grivicich, G.J. Peters, and G. Schwartsmann Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines Eur J Cancer 35 1999 1851 1861
16. S. Mullany, P.A. Svingen, S.H. Kaufmann, and C. Erlichman Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity Cancer Chemother Pharmacol 42 1998 391 399
17. J. Taïeb, T. Lecomte, and T. Aparicio FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study Ann Oncol 18 2007 498 503
18. H. Kelly, and R.M. Goldberg Systemic therapy for metastatic colorectal cancer: current options, current evidence J Clin Oncol 23 2005 4553 4560
19. R. Klapdor, M. Bahlo, and A. Babinsky Further evidence for prolongation of survival of pancreatic cancer patients by efficacy orientated sequential polychemotherapy (EOSPC) based on serial tumor marker determinations (CA 19-9/CEA) Anticancer Res 25 2005 1687 1691
20. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
21. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 2006 Cancer Therapy Evaluation Program Bethesda, MD http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf
22. N.K. Aaronson, S. Ahmedzai, and B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
23. D. Osoba, G. Rodrigues, and J. Myles Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1998 139 144
24. F. Bonnetain, L. Dahan, and E. Maillard Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma Eur J Cancer 46 2010 2753 2762
25. M. Tempero, W. Plunkett, and V. Ruiz Van Haperen Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 2003 3402 3408
26. E. Poplin, Y. Feng, and J. Berlin Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group J Clin Oncol 27 2009 3778 3785
27. U. Pelzer, I. Schwaner, and J. Stieler Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group Eur J Cancer 47 2011 1676 1681
28. J. Whitehead One-stage and two-stage designs for phase II clinical trials with survival endpoints Stat Med 2014 10.1002/sim.6196
29. L. Seymour, S.P. Ivy, and D. Sargent The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee Clin Cancer Res 16 2010 1764 1769